new open-label Xolair study

[Guest guest]

http://www.resmedjournal.com/article/S0954-6111(08)00203-5/abstract

Respir Med. 2008 Jul 25.

Effectiveness of omalizumab in patients with inadequately controlled severe

persistent allergic asthma: An open-label study.

Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.

North West Lung Centre, Wythenshawe Hospital, Southmoor Road, Manchester, M23

9LT, UK.

Adding omalizumab . . . is efficacious in patients with inadequately controlled

severe persistent allergic asthma . . . , with further efficacy observed in

patients judged to have responded to therapy which may more accurately

illustrate the actual benefit of omalizumab therapy in clinical practice. The

naturalistic setting of this study confirms the benefits observed in

double-blind randomized clinical trials.